• BioTime to Present Data from OpRegen® Phase I/IIa Clinical Study at the Association for Research …

    ALAMEDA, Calif.–(BUSINESS WIRE)–Apr 16, 2019–BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company …

    Read More
  • 0 0